Azadeh Shoaibi, PhD, MHS

Associate Director Post-market Surveillance
FDA
Silver Spring, United States

Disclosure information not submitted.

Presentation(s):

• Assessment of Potential Adverse Events Following the 2022–2023 Seasonal Influenza Vaccines Among U.S. Adults Aged 65 Years and Older

  Monday, August 26, 2024
  2:30 PM – 2:45 PM CEST

• Effectiveness Over Time of a Complete Primary Series of the Original, Monovalent COVID-19 Vaccines Among Adults Aged 18-64 Years in the United States

  Tuesday, August 27, 2024
  9:15 AM – 9:30 AM CEST

• Events on Day Zero of Follow-Up: Considerations for Cohort Studies of Adverse Events After COVID-19 Diagnosis

  Tuesday, August 27, 2024
  1:00 PM – 1:15 PM CEST

• Risk of Neurologic or Immune-Mediated Adverse Events After COVID-19 Diagnosis in the United States

  Wednesday, August 28, 2024
  1:30 PM – 1:45 PM CEST

• Risk of Cardiovascular Adverse Events After COVID-19 Diagnosis in the United States

  Wednesday, August 28, 2024
  2:45 PM – 3:00 PM CEST